Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hormones and Bone Tissue

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...

Skeleton and Calcium Homeostasis

Skeleton and Calcium Homeostasis

Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.

Synthesis and Functions of Calcitonin

Synthesis and Functions of Calcitonin

Calcitonin, a vital polypeptide hormone, regulates calcium levels within body fluids. It is released by the parafollicular cells, also known as C cells, situated in the follicular epithelium of the thyroid gland. Calcitonin responds to fluctuations in blood calcium levels and the influence of gastrointestinal hormones like gastrin and cholecystokinin.
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...

Bone Disorders

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...

Osteoclasts in Bone Remodeling

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.

JAMA internal medicine·2022

Same author

Advance care planning among African American patients on haemodialysis and their end-of-life care preferences.

Journal of renal care·2021

Same author

Weight, Weight Perception and Self-reported Access to Transplantation in African American Hemodialysis Patients.

Kidney medicine·2019

Same author

A Clinical Prediction Score to Guide Referral of Elderly Dialysis Patients for Kidney Transplant Evaluation.

Kidney international reports·2017

Same author

Medullary Microvascular Thrombosis and Injury in Sickle Hemoglobin C Disease.

Journal of the American Society of Nephrology : JASN·2015

Same author

The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study.

Therapeutic advances in chronic disease·2015

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Published on: April 13, 2022

Cinacalcet-induced hungry bone syndrome.

Eric S Lazar¹, Nicole Stankus

¹Department of Medicine, Section of Nephrology, University of Chicago, Chicago, Illinois 60637, USA.

Seminars in Dialysis

|January 25, 2007

Summary

Cinacalcet can cause rare, prolonged, symptomatic hypocalcemia in dialysis patients. This case highlights a potential risk previously unreported for this calcimimetic drug.

Area of Science:

Nephrology
Endocrinology
Pharmacology

Background:

Secondary hyperparathyroidism is common in end-stage renal disease (ESRD) patients.
Cinacalcet, a calcimimetic, effectively lowers parathyroid hormone (PTH) levels.
Common side effects include nausea and vomiting; hypocalcemia is considered rare.

Observation:

A 66-year-old hemodialysis patient with severe secondary hyperparathyroidism (PTH 1091 pg/mL) was treated with cinacalcet.
Two weeks post-initiation, the patient developed symptomatic hypocalcemia with muscle twitching.
This required hospitalization and continuous intravenous calcium infusion.

Findings:

The patient experienced prolonged, symptomatic hypocalcemia attributed to cinacalcet.
PTH levels decreased significantly (1091 to 176 pg/mL) during the hypocalcemic episode.

Related Experiment Videos

Last Updated: Jul 17, 2026

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Evaluation of Amino Acid Consumption in Cultured Bone Cells and Isolated Bone Shafts

Published on: April 13, 2022

This represents the first reported case of cinacalcet-induced persistent and symptomatic hypocalcemia.

Implications:

Cinacalcet may induce severe hypocalcemia, mimicking hungry bone syndrome.
Clinicians should monitor calcium levels closely in ESRD patients initiating cinacalcet.
This case expands the known side effect profile of cinacalcet in secondary hyperparathyroidism management.